| Status | Awaiting development |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Further information | As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Durvalumab with tremelimumab within its marketing authorisation for treating limited-stage small-cell lung cancer after chemoradiation. Please note that following on from advice received from the company the timelines for this appraisal are to be confirmed. The appraisal will be rescheduled to align with latest regulatory expectations and an update on the revised timelines will be provided when further information is available. |
| Process | TA |
| ID number | 5097 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 17 July 2023 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early October 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early December 2024. |
| 28 November 2022 | Awaiting development |
| 28 November 2022 | As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Durvalumab with tremelimumab within its marketing authorisation for treating limited-stage small-cell lung cancer after chemoradiation. Please note that following on from advice received from the company the timelines for this appraisal are to be confirmed. The appraisal will be rescheduled to align with latest regulatory expectations and an update on the revised timelines will be provided when further information is available. |
For further information on our processes and methods, please see our CHTE processes and methods manual